--- title: "Market Orphans or Hidden Gems? Why These 9 Stocks Are Lumped Together in 2026" type: "News" locale: "en" url: "https://longbridge.com/en/news/292261243.md" description: "A bizarre hodgepodge of AI chasers, biotech lottery tickets, and legacy giants reveals the bloodbath of the 2026 mid-market. Stop buying the hype and look at who is actually making money." datetime: "2026-07-10T02:03:06.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292261243.md) - [en](https://longbridge.com/en/news/292261243.md) - [zh-HK](https://longbridge.com/zh-HK/news/292261243.md) --- # Market Orphans or Hidden Gems? Why These 9 Stocks Are Lumped Together in 2026 Here is the brutal truth about the 2026 market: if you aren't Apple, Microsoft, or Nvidia, you are fighting for scraps. This week, I am looking at a truly bizarre basket of market orphans. From space defense to cross-border trucking, these nine companies have almost nothing in common—except they are all desperately trying to convince investors they still have a moat. Let's look at who is actually building something real, and who is just asleep at the wheel. First up is **Appian (APPN.US)**. They have been pitching low-code enterprise software for years, but since that is no longer cool, they launched Agent Studio in 2025 to ride the AI wave. They posted **USD 202.2M** in revenue for Q1 2026 and finally flipped to profitability. That is fine, but my question is, why aren't you moving faster? The stock has been choppy this year, and the market clearly wants more proof of exponential growth, not just defensive maneuvering. Then we have **Phunware (PHUN.US)**, a mobile enterprise software company that is now inexplicably pivoting to generative AI. This is stupid and here's why: they made a paltry **USD 800K** in Q4 2025 revenue, bled cash all year, and just swapped out their CEO again in May 2026 to pitch a "2.0 strategy." Good luck with that. It sounds less like a strategic upgrade and more like a desperate Hail Mary. **Bit Digital (BTBT.US)** is another classic 2026 playbook—a crypto miner masquerading as an AI infrastructure titan. They bought 70% of WhiteFiber to rent out GPUs, double-dipping in Ethereum and AI workloads. Shares have been highly volatile recently. Truth be told, management is just chasing whatever sector has the juiciest multiple. You cannot be both a crypto native and a pure-play AI vendor; eventually, the market sees right through it. Amidst all this fluff, **Karman Holdings (KRMN.US)** actually looks remarkably substantial. The space and defense contractor pulled off an IPO in 2025 and reported a record **USD 151.2M** in Q1 2026 revenue, up 51% year-over-year. The stock has cooled significantly from its early 2026 peak, but they hold actual Pentagon contracts. They are making real, tangible missile components, not vaporware. Biotech, on the other hand, is always a waiting game. **Compugen (CGEN.US)** just delivered a Q1 2026 net loss of **USD 7.7M**, though they have USD 134.9M in cash to survive until 2029. They are developing cancer immunotherapies, but we won't see interim trial data until 2027. Wake me up when the data hits. If you enjoy that kind of torture, be my guest. By contrast, **SpyGlass Pharma (SGP.US)** has a much cleaner narrative. They successfully pulled off a **USD 172.5M** IPO in February 2026 to fund their glaucoma implants, which release drugs continuously for three years. It is a real problem with a highly elegant solution, and the stock has been outperforming since its debut. Who else? **Freight Technologies (FRGT.US)**, a NAFTA cross-border B2B trucking platform, suddenly announced an "AI-first" pivot in April 2026 while simultaneously exploring a strategic sale. Translation: they are running out of runway. The stock is severely lagging, which is a massive red flag. Who wants to buy an AI follower that cannot even nail its core freight business? If you want an old-school, boring business, look at **Unifi (UFI.US)**. They turn plastic bottles into recycled yarn. No AI, no crypto. But they significantly narrowed their losses in Q3 FY26 and improved their margins. In a group filled with fake tech prosperity, a legacy textile company squeezing cash out of literal garbage is oddly comforting. Finally, why is **Ping An (PNGAY.US)**, a massive Chinese insurance titan with over **220 million** customers, sitting in this basket of micro-caps? The ADR has struggled recently as it navigates a challenging macro environment. Putting Ping An next to Phunware is like parking an aircraft carrier next to a leaky canoe. Whoops! My view is simple: in a market obsessed with Trillion-dollar AI models, the mid-tier ecosystem is an absolute bloodbath. You can pivot to frontier tech all you want, but if your core business is bleeding, no algorithm will save you. Fix your cash flow, or prepare to be wiped out. _This article does not constitute investment advice._ ### Related Stocks - [SGP.US](https://longbridge.com/en/quote/SGP.US.md) - [FRGT.US](https://longbridge.com/en/quote/FRGT.US.md) - [CGEN.US](https://longbridge.com/en/quote/CGEN.US.md) - [UFI.US](https://longbridge.com/en/quote/UFI.US.md) - [KRMN.US](https://longbridge.com/en/quote/KRMN.US.md) - [APPN.US](https://longbridge.com/en/quote/APPN.US.md) - [PHUN.US](https://longbridge.com/en/quote/PHUN.US.md) - [PNGAY.US](https://longbridge.com/en/quote/PNGAY.US.md) - [BTBT.US](https://longbridge.com/en/quote/BTBT.US.md) ## Related News & Research - [Appian (APPN) Reports Earnings Tomorrow: What To Expect](https://longbridge.com/en/news/294906392.md) - [H.C. Wainwright Keeps Their Buy Rating on Compugen (CGEN)](https://longbridge.com/en/news/294794759.md) - [SpyGlass Pharma Insiders Enjoying US$1.1m Appreciation On US$2.16m Investment](https://longbridge.com/en/news/294956943.md) - [Ping An Group Upgrades Longevity Management Service System, Unveils 11 Health Longevity Centers Nationwide](https://longbridge.com/en/news/294343576.md) - [Compugen publishes corporate presentation on AI-driven immuno-oncology antibody pipeline](https://longbridge.com/en/news/294684055.md)